ArticleProstate international2018
Impact of United States Preventive Services Task Force recommendations on prostate biopsy characteristics and disease presentation at a tertiary-care medical center.
Article in Prostate international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Temporal trends and regional disparities in prostate cancer mortality in the United States, 1999-2023: an analysis of the CDC WONDER database.BMC public health · 2025Article
- A Community-Based Prostate Cancer Screening and Education Program for Asian American Men in Medically Underserved Communities.International journal of environmental research and public health · 2024Article
- Increasing aggressive prostate cancer.The Canadian journal of urology · 2022Article
- Molecular genetic testing does not improve the detection of fluoroquinolone resistance before transrectal prostate biopsy.Prostate international · 2022Article
- Non-infectious complications following transrectal prostate needle biopsy - Outcomes from over 8000 procedures.Prostate international · 2022Article
- Comparative effectiveness of robotic and open radical prostatectomy.Translational andrology and urology · 2021Review
- Impact on prostate cancer clinical presentation after non-screening policies at a tertiary-care medical center- a retrospective study.BMC urology · 2021Article
- A Trend Toward Aggressive Prostate Cancer.Reviews in urology · 2020Article
- Prostate Biopsy Features: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force Prostate Cancer Screening Guidelines With Emphasis on African American and Septuagenarian Men.Reviews in urology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate early consequences of 2012 United States Preventive Services Task Force (USPSTF) recommendations for decreased prostate-specific antigen (PSA) screening on prostate biopsy characteristics and prostate cancer presentation. MATERIALS AND
methodsA single tertiary-care institution, multisurgeon, prospectively maintained database was queried for patients undergoing prostate biopsy from October 2005 to September 2016. Patient demographics, biopsy characteristics, and extent of disease were reported. Patient cohorts before and after USPSTF recommendations were compared using two-sample
resultsA total of 2,000 patients were analyzed, including 1,440 patients before and 560 patients after USPSTF recommendations. Following the recommendations, patients had higher prebiopsy PSA (5.90 vs. 6.70,
conclusionsAfter 2012 USPSTF guidelines, patients presented with higher PSA with prostate cancer were detected more frequently. More adverse, pathologic prostate cancer features were found on biopsy with the extent of disease implicating locally advanced/metastatic disease. These findings should be considered when counseling patients about prostate cancer screening importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.